EVMN

Following the mid-June Bullish Pivot Point, price has cleared and held above the 9EMA and 20EMA and is now testing the 50 DMA overhead. Medium-term bias remains Bullish in this Stage 1 consolidation with a mean-reversion tilt. Short-term pullback into rising EMAs offers a favorable entry. Overall, initiate a Buy Now on the pullback into the 9/20 EMA zone, using a pullback interaction as support.

• ↑Clear Street reiterates Buy with $53 PT on strong atopic dermatitis pipeline
• ↑EVMN shares rose 20.1% in two weeks following FOCIS 2026 clinical updates
• ↓Profitability is weak with a low profitability score and no near-term earnings